Software matches genomic test results to cancer treatment options, including trials and experimental drugs, via intelligent search and molecular science
MolecularMatch, a personalized cancer treatment company that works with labs, hospitals, genomic cores and physicians to connect cancer patients to treatment options, launched its MM LAB software today at The Molecular Medicine Tri-Conference.
MM LAB, which is available through an online portal, allows pathology labs and others to match patients’ test results to personalized cancer treatments, including clinical trials and experimental drugs, in real-time.
It is based on the already available, public-facing MolecularMatch
cancer treatment search engine. “We’ve taken a time-consuming, manual task that usually happens after lab results are returned, and automated it with an intelligent, science-based, Google-like search,” said MolecularMatch CEO Kevin Coker. “With MM LAB, oncologists and patients get test results and easily understandable treatment
options all at once, rather than having to wait even longer to find and begin a course of treatment.”
After test results are matched to treatments in MM LAB, the options are curated by the client laboratory's staff and included in the reports sent back to physicians and patients.
How MM LAB Search Works:
“MolecularMatch provides a powerful resource for molecular pathologists,” said Christopher Corless, MD, PhD, Chief Medical Officer of OHSU Knight Diagnostic Laboratories. “Identifying treatment options - particularly trials - is a time-consuming task. The MolecularMatch platform allows our team to efficiently match complex genomic test data to appropriate treatment options in much less time.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.